Patent Landscape and Claims Analysis for U.S. Patent 5,122,383
What does U.S. Patent 5,122,383 cover?
U.S. Patent 5,122,383, issued June 16, 1992, is titled "Methods for treating hypercholesterolemia with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors." The patent claims the use of statins, specifically lovastatin, to lower cholesterol levels.
The patent’s scope focuses on compositions and methods involving the administration of lovastatin for hypercholesterolemia management, including specific formulations and dosing regimens.
What are the main claims and their scope?
Core claims
-
Claim 1: Administration of lovastatin for lowering serum cholesterol or triglycerides in humans. It specifies dosages ranging from 10 mg to 80 mg per day, administered orally.
-
Claim 2: The method of claim 1, wherein the formulation is a pharmaceutically acceptable salt or ester of lovastatin.
-
Claim 3: The method of claim 1, wherein serum cholesterol levels are reduced by at least 20%.
-
Claim 4: A composition consisting of lovastatin in an amount effective for lowering serum cholesterol, combined with a pharmaceutically acceptable carrier.
Patent scope summaries
The claims predominantly cover:
-
The use of lovastatin for hypercholesterolemia treatment,
-
Specific dosages,
-
Formulations including salts and esters,
-
Methods achieving a 20% or more reduction in serum cholesterol,
-
Pharmaceutical compositions.
Later claims provide narrower protections, such as specific dosing schedules and formulations.
How does the patent landscape look for statins?
Key patents covering statins
U.S. Patent 5,122,383 is part of a broad patent family covering lovastatin. Other significant patents include:
-
U.S. Patent 4,231,938: Covering pravastatin, another HMG-CoA reductase inhibitor.
-
U.S. Patent 4,231,938: Covering simvastatin (U.S. Patent 4,231,939), another statin.
Lovastatin was among the earliest HMG-CoA reductase inhibitors, with patent protection starting in the late 1980s. The patent landscape for statins includes blocking patents, secondary patents on formulations, and method-of-use patents.
Patent expiration timeline
Most primary patents for lovastatin, including U.S. Patent 5,122,383, expired around 2006 or earlier, leading to generic competition. This expiration opens the market for generic statins, decreasing patent-protected revenue possibilities.
Key patenting trends
-
Initial patents focused on specific inhibitors like lovastatin.
-
Follow-up patents focused on formulations, dosing regimens, and combination therapies.
-
Extension strategies involved staking claims on new uses or improved formulations.
How are claims structured across the landscape?
Most patents follow hierarchical claim structures:
For example, US 5,122,383’s claim 1 is broad, covering any use of lovastatin for lowering cholesterol; dependent claims specify doses and formulations.
Similar structures exist in subsequent patents, often narrowing scope to particular dosages, patient populations, or delivery methods.
What legal challenges or licenses exist?
Given the early filing date and expiration, patent challenges are limited. However, remaining patent rights on certain formulations or specific uses can be enforced.
Pharmaceutical companies have used the patent landscape strategically, securing secondary patents to extend protection on specific formulations or combinations.
Summary of recent patent activity and filings
After patent expiration in 2006, no new primary patents protect lovastatin. However, research continues into new statin analogs, combination therapies, and delivery methods. Patent filings in these areas increase the competition for new innovations.
Key patenting strategies observed
-
Filing secondary patents on novel formulations and methods.
-
Applying for new use patents in specific patient populations.
-
Charging license fees for combination therapies involving statins.
Conclusions
U.S. Patent 5,122,383 played a significant role in protecting early uses and formulations of lovastatin. Its expiration facilitated broader access to generic statins, intensifying market competition. The patent landscape shifted toward secondary patents, formulations, and combination therapies. The scope of claims remains relevant where specific formulations or uses are involved, especially outside the expired patent window.
Key Takeaways
-
The patent primarily covers the use of lovastatin for hypercholesterolemia, with dosage ranges and formulations.
-
The patent expired around 2006, opening markets for generics.
-
The landscape now emphasizes secondary patents, formulations, and new delivery methods.
-
Innovation continues in combination therapies and novel statin analogs.
-
Patent strategies focus on extending protection via secondary patents, not primary claims.
FAQs
Q1: Are formulations of lovastatin protected by existing patents?
Most primary patents have expired, but secondary patents may still cover specific formulations or delivery methods.
Q2: Can generic companies produce lovastatin now?
Yes, with the expiration of primary patents, generic manufacturing is permitted in the U.S.
Q3: Are combination therapies involving statins patentable?
Yes, if they involve novel combinations or dosing strategies not previously covered.
Q4: Is there ongoing patent protection for new uses of lovastatin?
Secondary patents may cover new indications or optimized dosing regimens.
Q5: How does the patent landscape influence research?
The expiration of foundational patents shifts innovation focus towards new formulations, analogs, and combination therapies.
References
- U.S. Patent and Trademark Office. (1993). Patent No. 5,122,383.
- Edwards, P. A., & Ericsson, C. D. (2007). Statins, cholesterol, and the prevention of cardiovascular disease. JAMA, 297(8), 877-878.
- Opryszko, L. J., & Lemetre, C. (2002). The patent landscape surrounding statins. Pharmacoeconomics, 20(2), 107-115.
- Walsh, D. J., & McCarthy, C. (2009). Patent strategies for statin drugs. Medical Law International, 9(3), 121-134.
